Abstract：
Targeted therapy has the potential to be used in the neoadjuvant setting for odontogenic tumors, reducing the morbidities associated with major surgery. In this regard, the aim of this study was to summarize the current evidence on the different forms of targeted therapy, effectiveness, and drawbacks of this course of treatment. Four databases were searched electronically without regard to publication date or language. Grey literature searches and manual searches were also undertaken. Publications with sufficient clinical data on targeted therapy for odontogenic tumors were required to meet the criteria for eligibility. The analysis of the data was descriptive. A total of 15 papers comprising 17 cases (15 ameloblastomas and 2 ameloblastic carcinomas) were included. Numerous mutations were found, with BRAF V600E being most common. Dabrafenib was the most utilized drug in targeted therapy. Except for one case, the treatment reduced the size of the lesion (16/17 cases), showing promise. Most of the adverse events recorded were mild, such as skin issues, voice changes, abnormal hair texture, dry eyes, and systemic symptoms (e.g., fatigue, joint pain, and nausea). It is possible to reach the conclusion that targeted therapy for ameloblastoma and ameloblastic carcinoma may be a useful treatment strategy, based on the findings of the included studies.
摘要：
靶向治疗有可能用于牙源性肿瘤的新辅助治疗，减少与大手术相关的发病率。在这方面,这项研究的目的是总结目前不同形式的靶向治疗的证据，有效性,和这个疗程的弊端。以电子方式搜索了四个数据库，而不考虑出版日期或语言。还进行了灰色文献检索和手动检索。需要有足够的关于牙源性肿瘤靶向治疗的临床数据的出版物来满足资格标准。对数据的分析是描述性的。共包括15篇论文，包括17例（15例成釉细胞瘤和2例成釉细胞癌）。发现了许多突变，与BRAFV600E是最常见的。Dabrafenib是靶向治疗中最常用的药物。除了一个案子,治疗减少了病变的大小（16/17例），显示承诺。记录的大多数不良事件都是轻度的，比如皮肤问题,声音变化,头发纹理异常，干眼,和全身症状(例如，疲劳,关节痛,和恶心）。结论：成釉细胞瘤和成釉细胞癌的靶向治疗可能是一种有用的治疗策略，根据纳入研究的结果。
